[1] McGregor CGA, Byrne GW. Porcine to human heart transplantation: is clinical application now appropriate?[J]. J Immunol Res, 2017, 2017: 2534653.
[2] Patel MS, Louras N, Vagefi PA. Liver xenotransplantation[J]. Curr Opin Organ Transplant, 2017, 22(6): 535–540.
[3] Shah JA, Patel MS, Elias N, et al. Prolonged survival following pig-to-primate liver xenotransplantation utilizing exogenous coagulation factors and costimulation blockade[J]. Am J Transplant, 2017, 17(8): 2178–2185.
[4] Iwase H, Kobayashi T. Current status of pig kidney xenotransplantation[J]. Int J Surg, 2015, 23(Pt B): 229–233.
[5] Fukui A, Yokoo T. Kidney regeneration using developing xenoembryo[J]. Curr Opin Organ Transplant, 2015, 20(2): 160–164.
[6] Wilczek P, Lesiak A, Niemiec-Cyganek A, et al. Biomechanical properties of hybrid heart valve prosthesis utilizing the pigs that do not express the galactose-α-1,3-galactose (α-Gal) antigen derived tissue and tissue engineering technique[J]. J Mater Sci Mater Med, 2015, 26(1): 5329.
[7] Laird C, Burdorf L, Pierson RN 3rd. Lung xenotransplantation: a review[J]. Curr Opin Organ Transplant, 2016, 21(3): 272–278.
[8] Sahara H, Watanabe H, Pomposelli T, et al. Lung xenotransplantation[J]. Curr Opin Organ Transplant, 2017, 22(6): 541–548.
[9] Abalovich A, Matsumoto S, Wechsler CJ, et al. Level of acceptance of islet cell and kidney xenotransplants by personnel of hospitals with and without experience in clinical xenotransplantation[J]. Xenotransplantation, 2017, 24(4): 1–5.
[10] Cooper DKC, Matsumoto S, Abalovich A, et al. Progress in clinical encapsulated islet xenotransplantation[J]. Transplantation, 2016, 100(11): 2301–2308.
[11] Cooper DKC, Ekser B, Ramsoondar J, et al. The role of genetically engineered pigs in xenotransplantation research[J]. J Pathol, 2016, 238(2): 288–299.
[12] Dong X, Hara H, Wang Y, et al. Initial study of 1,3- galactosyltransferase gene-knockout/CD46 pig full-thickness corneal xenografts in rhesus monkeys[J]. Xenotransplantation, 2017, 24(1): 1–12.
[13] Ekser B, Li P, Cooper DKC. Xenotransplantation: past, present, and future[J]. Curr Opin Organ Transplant, 2017, 22(6): 513–521.
[14] Cooper DKC, Pierson RN 3rd, Hering BJ, et al. Regulation of clinical xenotransplantation-time for a reappraisal[J]. Transplantation, 2017, 101(8): 1766–1769.
[15] Higginbotham L, Mathews D, Breeden CA, et al. Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model[J]. Xenotransplantation, 2015, 22(3): 221–230.
[16] Cooper DKC, Ezzelarab MB, Hara H. Low anti-pig antibody levels are key to the success of solid organ xenotransplantation: But is this sufficient?[J]. Xenotransplantation, 2017, 24(6): 1–6.
[17] Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha- 1,3-galactosyltransferase knockout pigs by nuclear transfer cloning[J]. Science, 2002, 295(5557): 1089–1092.
[18] Dai Y, Vaught TD, Boone J, et al. Targeted disruption of the alpha1, 3-galactosyltransferase gene in cloned pigs[J]. Nat Biotechnol, 2002, 20(3): 251–255.
[19] McGregor CGA, Ricci D, Miyagi N, et al. Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts[J]. Transplantation, 2012, 93(7): 686–692.
[20] McGregor C, Byrne G, Rahmani B, et al. Physical equivalency of wild type and galactose α 1,3 galactose free porcine pericardium; a new source material for bioprosthetic heart valves[J]. Acta Biomater, 2016, 41: 204–209.
[21] Mohiuddin MM, Corcoran PC, Singh AK, et al. B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8 months[J]. Am J Transplant, 2012, 12(3): 763–771.
[22] Chen G, Qian H, Starzl T, et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys[J]. Nat Med, 2005, 11(12): 1295–1298.
[23] Byrne GW, Du Z, Stalboerger P, et al. Cloning and expression of porcine 1,4 N-acetylgalactosaminyl transferase encoding a new xenoreactive antigen[J]. Xenotransplantation, 2014, 21(6): 543–554.
[24] Lee W, Hara H, Ezzelarab MB, et al. Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs[J]. Xenotransplantation, 2016, 23(2): 137–150.
[25] Burlak C, Bern M, Brito AE, et al. N-linked glycan profiling of GGTA1/CMAH knockout pigs identifies new potential carbohydrate xenoantigens[J]. Xenotransplantation, 2013, 20(5): 277–291.
[26] Petersen B, Frenzel A, Niemann H. Efficient generation of a triple knockout (GGTA1/CMAH/ASGR1) of xenorelevant genes in pig fibroblasts[J]. Xenotransplantation, 2015, 22(Suppl S1): S40.
[27] Estrada JL, Martens G, Li P, et al. Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/4GalNT2 genes[J]. Xenotransplantation, 2015, 22(3): 194–202.
[28] Zhang RJ, Wang Y, Chen L, et al. Reducing immunoreactivity of porcine bioprosthetic heart valves by genetically-deleting three major glycan antigens, GGTA1/4GalNT2/CMAH[J]. Acta Biomater, 2018, 72: 196–205.
[29] Wang ZY, Martens GR, Blankenship RL, et al. Eliminating xenoantigen expression on swine RBC[J]. Transplantation, 2017, 101(3): 517–523.
[30] Amano S, Shimomura N, Kaji Y, et al. Antigenicity of porcine cornea as xenograft[J]. Curr Eye Res, 2003, 26(6): 313–318.
[31] Hara H, Koike N, Long C, et al. Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs[J]. Invest Ophthalmol Vis Sci, 2011, 52(8): 5278–5286.